Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.49 |
| ▸ | GCGR | P47871 | 3/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426390 | 1.00 | RAF1 (0.57) | RAF1MAPK14ALOX5MAPK13GCGR | |
| SCHEMBL4422522 | 0.88 | MAPK14 (0.59) | MAPK14ALOX5MAPK13GCGRMAPK12 | |
| SCHEMBL5079652 | 0.88 | MAPK14 (0.59) | MAPK14ALOX5MAPK13GCGRMAPK12 | |
| SCHEMBL5082102 | 0.82 | TEK (0.60) | RAF1MAPK14ALOX5MAPK13GCGR | |
| SCHEMBL4429243 | 0.82 | TEK (0.60) | RAF1MAPK14ALOX5MAPK13GCGR | |
| SCHEMBL16497611 | 0.80 | RAF1 (0.48) | RAF1MAPK14ALOX5MAPK13GCGR | |
| SCHEMBL4426392 | 0.79 | MAPK14 (0.52) | MAPK14ALOX5MAPK13GCGRMAPK12 | |
| SCHEMBL5488836 | 0.79 | ALOX5 (0.47) | MAPK14ALOX5MAPK13GCGRMAPK12 | |
| SCHEMBL7445283 | 0.79 | MAPK14 (0.58) | MAPK14ALOX5MAPK13GCGRMAPK12 | |
| SCHEMBL8488767 | 0.77 | ALDH1A1 (0.47) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | claimed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | RAF1 1862/4885MAPK14 3769/4885ALOX5 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.